Meag Munich Ergo Kapitalanlagegesellschaft MBH lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 84.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,000 shares of the insurance provider’s stock after selling 11,093 shares during the quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Humana were worth $487,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. WFG Advisors LP raised its stake in Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 20 shares during the period. Acrospire Investment Management LLC bought a new stake in Humana during the 2nd quarter valued at approximately $120,000. Northwestern Mutual Wealth Management Co. raised its stake in Humana by 139.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after purchasing an additional 325 shares during the period. Fiduciary Trust Co. bought a new stake in Humana during the 2nd quarter valued at approximately $135,000. Finally, Westbourne Investment Advisors Inc. bought a new stake in Humana during the 2nd quarter valued at approximately $205,000. 96.15% of the stock is currently owned by institutional investors.
Humana Inc. (NYSE:HUM) traded down $1.38 on Wednesday, reaching $239.56. The company had a trading volume of 1,925,400 shares, compared to its average volume of 1,379,490. Humana Inc. has a one year low of $186.25 and a one year high of $264.56. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The stock has a market cap of $34,420.71, a PE ratio of 20.56, a P/E/G ratio of 1.66 and a beta of 0.91.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the previous year, the business earned $3.18 EPS. Humana’s revenue was down 3.0% compared to the same quarter last year. sell-side analysts anticipate that Humana Inc. will post 11.63 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is currently 12.59%.
Several analysts recently issued reports on HUM shares. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. BidaskClub downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Piper Jaffray Companies lifted their target price on Humana to $280.00 and gave the company an “overweight” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company reissued an “outperform” rating and set a $275.00 target price (up previously from $230.00) on shares of Humana in a research note on Wednesday, September 20th. Thirteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $252.81.
In related news, VP Timothy S. Huval sold 7,803 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the completion of the transaction, the vice president now owns 8,831 shares in the company, valued at approximately $2,279,634.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total value of $2,534,574.00. Following the transaction, the insider now owns 18,042 shares of the company’s stock, valued at approximately $4,672,878. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,660 shares of company stock valued at $5,319,600. 0.80% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Humana Inc. (HUM) Position Cut by Meag Munich Ergo Kapitalanlagegesellschaft MBH” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/11/15/humana-inc-hum-position-cut-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.